GUMDROP : AOH - PROSELICA - Randomized, open label study comparing Cabazitaxel at 20 mg per m2 and at 25 mg per m2 every 3 weeks in combination with Prednisone for the treatment of mCRPC previously treated with Docetaxel containing Regimen
Created by Dipak Dahal, last modified on Apr 24, 2012
Description: |
Second Line Chemotherapy with Cabazitaxel for Prostate adenocarcinoma that is resistant to hormone therapy and previously treated with a Docetaxel-containing regimen.
Patient must have documented progression of disease during or within 6 months after prior hormone therapy and disease progression or after Docetaxel-containing therapy. |
Link: |
http://clinicaltrials.gov/ct2/show/NCT01308580 |
Site: |
Associates in Oncology/Hematology; P.C. - Rockville, MD
Phone: 301 424 6231 |
Principal Investigator: |
Manish Agrawal, MD |